Kornimate/medical-research-clean huggingface dataset:
wireless physiologic monitoring in postpartum women

Conditions: Maternal Death During Childbirth; Pregnancy Complications

Summary: to estimate the clinical effectiveness of wireless physiologic monitoring of women in the first 24 hours after cesarean delivery at mbarara regional referral hospital

women in sub-saharan africa have the highest rates of morbidity and mortality during childbirth. despite significant increases in facility-based childbirth, quality gaps at the facility have limited reductions in maternal deaths. infrequent monitoring of women around childbirth is a major gap in care that leads to delays in life-saving interventions. simple increases in staffing will not overcome this gap, thus necessitating new strategies. this project aims to use a simple wireless monitor to improve the detection of complications immediately after childbirth and allow clinicians to provide life-saving interventions when needed. using a hybrid clinical effectiveness-implementation approach women delivered by cesarean in mbarara, uganda will be recruited to wear a wireless physiologic monitor for 24 hours after delivery and their delivering obstetricians recruited to use the monitoring system, including the receipt of text message alerts should women develop abnormalities in physiologic signs. rates of morbidity and mortality will be compared with a control group of women delivered by the same obstetricians. clinical adoption and implementation will be assessed with the re-aim implementation framework and semi-structured interviews.

Eligibility criteria:
inclusion criteria: * emergency cesarean delivery at mrrh * able to provide consent or have a guardian/attendant present who can consent * willing to wear the biosensor for 24 hours * willing remain in the postpartum unit for 24 hours exclusion criteria: * admitted to icu directly after delivery * allergies or hypersensitivity to device materials

Keywords: vital sign monitoring maternal near miss maternal mortality maternal morbidity physiologic monitoring quality of care inpatient monitoring
the lama trial: laparoscopic correction of perforated peptic ulcer versus open correction

Conditions: Perforated Peptic Ulcer

Summary: this is a multicenter trial comparing laparoscopic correction of a perforated peptic ulcer with the open technique by upper laparotomy. hypothesis is that after laparoscopic correction will be discharged 3 days sooner due to less postoperative pain and complications.

as written above

Eligibility criteria:
inclusion criteria: * all patients clinical suspected for perforated peptic ulcer exclusion criteria: * pregnancy * younger than 18 years * unable to sign consent form

Keywords: laparoscopic peptic ulcer
quality of life in new treatable therapy as rabeprazole option for refractory reflux esophagitis

Conditions: Refractory Reflux Esophagitis

Summary: to investigate the efficacy and safety of pariet twice daily (b.i.d.) in patients with proton pump inhibitor-resistant reflux esophagitis


Eligibility criteria:
inclusion criteria; -proton pump inhibitor-resistant reflux esophagitis. (patients who have mucosal breaks (erosions, ulcers) on endoscopy) exclusion criteria; * patients with a history of hypersensitivity to any ingredients of pariet. * patients on atazanavir sulfate.

Keywords: rabeprazole sodium refractory reflux esophagitis
allps versus pvo randomized controlled trial

Conditions: Liver Tumors Not Resectable in One Surgical Procedure

Summary: this randomized phase ii trial compares how well associating liver partition with portal vein ligation for staged hepatectomy (alpps) or portal vein occlusion (pvo) works in treating patients with liver cancer. both treatments are types of 2-stage hepatectomies for removing liver cancer. alpps may be more effective than pvo in patients whose disease would traditionally be considered inoperable. * trial with surgical intervention


Eligibility criteria:
inclusion criteria: •patient may have primary or secondary hepatic malignancies with a flr/tlv \ 50 mmol/l, patient may be enrolled into the trial if flr/tlv is \< 40% or flr/bw ratio \< 0.8. * patient must have extensive liver tumors that would require portal vein embolization or a two-stage hepatectomy and portal vein embolization or ligation by the judgment of surgeons in the tumor board. * patient may have extrahepatic disease as long as it may be addressed after liver surgery and there is a tumor board decision to proceed with liver resection (mostly applicable to crc metastases). * patient may have received previous chemotherapy. * in cases of cholestasis, preoperative drainage procedures (ptc or ercp) are left up to judgement of physicians. * patient must be = 18 years of age. the patient population over 65 years old needs to be carefully included based on comorbidities. * patient may have undergone previous liver resection. * patient's location must be such that proper staging and follow-up may be performed. * patient's case must be presented at the multidisciplinary meeting attended by hepatobiliary surgeons, oncologists, hepatologists, and radiologists, or must be approved directly by dr. strasberg or dr. chapman. exclusion criteria: •patient must not have any significant concomitant diseases rendering him/her unsuitable for major liver surgery by the judgment of the physicians involved, especially if the patient is \> 65 years old. * patient must not have enrolled into a clinical trial within 4 weeks of study entry. * patient must not have peritoneal carcinomatosis or other extensive extrahepatic disease. * patient must not have advanced stages of carcinoma of the gallbladder (t3/t4) * patient must not have issues such as drug and/or alcohol abuse. * patient must not need major extrahepatic surgery (e.g. pancreas resection, gastric resection, rectal surgery) within 3 months of study entry. * patient must not be a candidate for liver transplantation in case of hcc. * patient must not be pregnant or breastfeeding. if a female of childbearing potential, patient must have a negative pregnancy test within 14 days of enrollment.
cognitive remediation in early phase psychosis

Conditions: Schizophrenia; Schizoaffective Disorder; Psychosis NOS

Summary: the purpose of the study is to investigate the effect of a 30 hour cognitive remediation program for young patients with early phase schizophrenia spectrum disorders on cognitive, clinical and functional outcome measures. the remediation program is integrated with whatever active rehabilitation the participant is currently attending (school, work, day program etc).


Eligibility criteria:
inclusion criteria: * early phase schizophrenia, schizoaffective disorder, psychosis nos * less than 5 years since start of adequate treatment for psychotic disorder * age between 18-40 * norwegian speaking (sufficiently to understand and complete assessments) exclusion criteria: * traumatic brain injury * neurological disorder as determined by medical history * iq below 70

Keywords: schizophrenia schizoaffective disorder psychosis early phase cognitive remediation functional outcome
retrospective evaluation of carvedilol versus captopril in chf patients

Conditions: Heart Failure; Heart Murmurs

Summary: this is a retrospective chart review examining our experience with carvedilol in chf secondary to left-to-right heart shunt lesions. the treatment group will be children who have received carvedilol. the control or comparison groups will be patients who have received either digoxin/furosemide or captopril for this indication. charts will be reviewed of patients who have been treated at children's healthcare of atlanta and as outpatients by sibley heart center cardiology between september 2000 and october 2005. patients will have been started on carvedilol prior to april 1, 2005 and only information up to october 1, 2005 will be used for this study. we will review approximately 50 charts for this study. we will evaluate the effectiveness of these medications at reducing symptoms of chf.

this is a retrospective chart review examining our experience with carvedilol in chf secondary to left-to-right heart shunt lesions. the treatment group will be children who have received carvedilol. the control or comparison groups will be patients who have received either digoxin/furosemide or captopril for this indication. charts will be reviewed of patients who have been treated at children's healthcare of atlanta and as outpatients by sibley heart center cardiology between september 2000 and october 2005. patients will have been started on carvedilol prior to april 1, 2005 and only information up to october 1, 2005 will be used for this study. we will review approximately 50 charts for this study. we will evaluate the effectiveness of these medications at reducing symptoms of chf.

Eligibility criteria:
inclusion criteria: children aged 0-18 years with a cardiac defect resulting in a left-to-right shunt (i.e. ventricular septal defect) who develop congestive heart failure. patient must have been treated with one of the study medications: carvedilol, digoxin, or furosemide. - exclusion criteria: patients who are not between 0-18, who do not have a defect resulting in left-to-right shunt, who do not have congestive heart failure and who have not been treated with one of the study medications: carvedilol, digoxin, or furosemide. -

Keywords: congestive heart failure, left-to-right shunt
root coverage comparing an allograft to a bovine xenograft

Conditions: Gingival Recession

Summary: root coverage with acellular dermal matrix using the coronally positioned tunnel technique comparing two different donor materials

thirty patients will be treated: 15 with a coronally positioned tunnel technique with novaderm® xenograft using continuous sling suture to secure both the graft and the flap (test treatment) and 15 with a coronally positioned tunnel technique with alloderm® allograft using continuous sling suture to secure both the graft and the flap (control treatment). sutures used for the control group will be maxon 5-0, 3/8 circle 13 mm needle for both the test and control groups. the coronally positioned tunnel technique was previously described by edwards pat allen (e.p. allen, center for advanced dental education, dallas, texas; course manual). each patient will provide at least one miller class i or ii facial recession defect, ≥ 3 mm. patients will be randomly selected by a coin toss to receive either the test or control treatment. mentor will toss the coin immediately prior to suturing. patients will be evaluated postoperatively for a period of 4 months. the examiner will be blinded and will not be aware of the patient treatment at any time during the term of the study. three exams for measurements will be performed per patient on total: preoperative, at week eight and 16 (4 months) postoperatively.

Eligibility criteria:
inclusion criteria: * at least one miller class i or ii mucogingival defect ≥ 3 mm (miller 1985). * the mucogingival defect must be on a non-molar tooth. * patients must be at least 18 years of age. exclusion criteria: * patients with debilitating systemic or diseases that significantly affect the periodontium. * patients with a known allergy to any of the materials that will be used in the study, including systemic antibiotics (tetracycline and doxycycline). * patients requiring antibiotic prophylaxis. * root surface restorations at the site of recession. * no detectable cej * patients who fail to maintain oral hygiene levels of at least 80% plaque free surfaces. * patients who are pregnant or lactating. * patients who use tobacco products (smoking or smokeless tobacco). * patients with alcohol abuse problems. * patients undergoing long-term steroid therapy. * history of previous root coverage procedures, graft or gtr, on the test teeth. * patients who fail to complete the informed consent form.
open-label, multi-center trial of zonisamide as adjunctive therapy in patients with uncontrolled partial epilepsy

Conditions: Epilepsy

Summary: the object of this study is to assess the efficacy and safety of zonisamide as adjunctive therapy in patients with uncontrolled partial epilepsy.

the object of this study is to assess the efficacy and safety of zonisamide as adjunctive therapy in patients with uncontrolled partial epilepsy. subject takes zonisamide for 16 weeks (4 weeks-titration period, 8 weeks maintenance period). dose range of zonisamide is 100 \~ 400 mg/day and target dose is 300 mg/day. after 16 weeks, zonisamide efficacy is measured by seizure reduction rate (each type of seizure: simple partial seizures \[sps\], complex partial seizures \[cps\], simple partial seizures evolving into generalized tonic-clonic convulsions \[sgtc\] and total seizure frequency), seizure free rate, responder rate, quality of life in epilepsy (qolie-31) and investigator's global evaluation scale. safety of zonisamide in this study will be estimated by adverse event profile, retention rate and dose of exposure. the duration of this clinical study is 2 years including period of subject enrollment.

Eligibility criteria:
inclusion criteria: 1. epilepsy patient over 15 years old who agrees with informed consent form 2. patient who has classifiable uncontrolled partial epilepsy according to international classification of epileptic seizures. 3. patient who has 3 \~ dozens of partial seizure (average more than once seizure per 4 weeks) last 12 weeks despite taking 1 \~ 3 antiepileptic drug(s). 4. patient who takes 1 \~ 3 marketed antiepileptic drug(s) excluding zonisamide at point of enrollment time. 5. before study visit, patient who takes stable dose of antiepileptic drug more than 4 weeks. exclusion criteria: 1. patient who has progressive central nervous system (cns) disorder and/or degenerative disease of the brain. 2. patient who experiences pseudoseizures and/or who has uncountable clusters. 3. patient who has serious systemic or drug metabolism affecting disorder . 4. upward of doubled normal glutamic oxaloacetic transaminase (got), glutamic pyruvic transaminase (gpt), bilirubin, blood urea nitrogen (bun), creatinine levels. 5. patient who has absolute neutrophil counts \<1800/mm3 or platelets \<100,000/mm3. 6. patient who has medical history of renal stones. 7. patient who is allergic to sulfonamide. 8. medical history of medicinal poisoning and/or alcoholism and/or serious psychological disorder. 9. pregnant women, lactating women, women of childbearing age who do not use a preventive method of conception. 10. a terminal patient and/or a scheduled surgical patient. 11. patient who has medication history of zonisamide. 12. patient who participated other clinical trial within the last 12 weeks at point of enrollment time of this study.
the effect of oral d-ribose in "baby boomers" with fatigue. a randomized, double-blind study

Conditions: Fatigue

Summary: d-ribose, a natural occurring pentose carbohydrate, has repeatedly shown to enhance high-energy phosphates and improve function following ischemia, states of congestive heart failure, and recently in subjects with lung disease. an initial preliminary, open label pilot study demonstrated a positive benefit of d-ribose in "baby-boomer" subjects aged 50 to 65 years old complaining of persistent fatigue. the objective of this study will build on the previously collected data to evaluate oral d-ribose vs. dextrose (administered as a supplement) in relatively healthy, yet fatigued subjects with a goal of improving their state of fatigue.


Eligibility criteria:
inclusion criteria: * presents with complaint of fatigue with duration longer than one month * males/females between the ages of 50 and 65 years of age * no previous clinical diagnosis of pulmonary, cardiac or metabolic disorders based on history * capable of performing a sub-maximal incremental treadmill exercise using cardiopulmonary analysis methods * normal blood pressure or those with mild, untreated pre-hypertension (\>120/70 or \< 140/90 mmhg) * able to be compliant with the supplement regimen, repeat clinical visits and completion of the study questionnaires * must be able to understand the consent form, agree to participate, and to execute their signature exclusion criteria: * not presently taking any adenine nucleotide enhancing supplements * history of non-compliance in previous studies * known to be pregnant * uncontrolled cardiac arrhythmias causing symptoms or unstable hemodynamics * moderate to severe gout * a diagnosis of arthritis of the lower extremities * mental impairment, inability to cooperate * history of acute non-cardiopulmonary disorder that may affect exercise performance, (e.g. infection, renal failure, thyrotoxicosis, etc.) * any disorder or condition that in the opinion of the study physician would render exercise unsafe or would impact exercise performance * any person who is incarcerated, or on a work release program additional exclusions observed and sequelae during initial baseline evaluation: * drop in systolic blood pressure of \>10 mm hg from baseline despite an increase in workload, when accompanied by other evidence of ischemia * moderately severe angina * increasing nervous system symptoms (e.g. ataxia, dizziness, or near syncope) * signs of poor perfusion (cyanosis or pallor) * technical difficulties monitoring the ecg or systolic blood pressure * subject's desire to stop * sustained ventricular tachycardia * electrocardiographic st elevation (+1.0 mm) in leads without diagnostic q-waves (other than v1 or avr)
method of clopidogrel pre-treatment undergoing conventional coronary angiogram in angina patients

Conditions: Angina, Stable

Summary: the study included 511 patients who underwent pci because of angina during 2010-2011 at three korean hospitals. clopidogrel-naïve patients received either a loading dose (ld; 600 mg at 2-24 h before the procedure) or routine maintenance therapy (75 mg/day for ≥5 days) plus either a 300-mg reload (rl) or only the maintenance dose (md).

elevation of myocardial infarction markers after coronary stenting reflects periprocedural myonecrosis or periprocedural myocardial infarction (pmi), which is associated with an increase in cardiac events and mortality. thus, we aimed to evaluate various clopidogrel pre-treatment methods for preventing pmi among patients undergoing conventional cag for stable angina pectoris. the method of clopidogrel pre-treatment undergoing conventional coronary angiogram in angina patients (mecca) study was a prospective, partially randomized, multi-center clinical trial. between october 2010 and july 2011, 511 patients underwent pci for angina pectoris at the korean university anam hospital, the eulji hospital, and the hanil general hospital. clopidogrel-naïve patients were enrolled to receive a loading dose (the ld group; clopidogrel at 600 mg, usually 2-24 h before the procedure) or routine therapy using daily clopidogrel doses (75 mg/day for ≥5 days). patients receiving daily doses were randomized to receive either an additional 300-mg reload (the rl group) or no additional loading (the maintenance dose \[md\] group). the 600-mg or 75-mg treatment regimens were selected at the physician's discretion. the primary outcome was creatinine kinase myocardial band (ck-mb) levels at several time points. the ck-mb levels were measured at baseline, 8 h, and 24 h, while troponin-i levels were measured at 8 h after the pci.

Eligibility criteria:
inclusion criteria: * written informed consent and, stable angina pectoris and, at least 1 ischemic evidence below 1. treadmil test positive 2. st-t change in resting ecg or 24-hour ecg 3. regional wall motion abnormality in echocardiography or cardiac mri 4. myocardial ischemia at mibi scan 5. moderate to severe stenosis at coronary ct angiography 6. chest pain or dyspnea exclusion criteria: * ast or alt \> 3 times upper normal limits * serum creatinine \> 2.0 mg/dl * chronic malaborption status (disorder or operation) * planned surgery within 1 year * pregnancy or breast-feeding patients * life expectancy \< 1 year

Keywords: clopidogrel loading maintenance dose periprocedural mi
arm and leg cycling exercise after stroke

Conditions: Stroke

Summary: it has been found that arm and leg cycling is similar to walking in terms of the muscle activation patterns and joint ranges of motion. in addition, arm and leg cycling and walking activate similar neural pathways. another advantage of arm and leg cycling is that it involves coordination of all four limbs in a rhythmic movement. this may be particularly beneficial given previous findings that arm movement contributes to the activation of leg muscles during walking in humans. this is achieved with interconnected neural pathways that link the arms to the legs. these neural interlimb connections remain intact in stroke victims, such that maximizing the contribution of the arms to the legs may increase coordination for walking. thus, the objectives of this research are to determine if arm and leg cycling can be used to increase the strength of interlimb connections and if this helps to improve walking ability in a post-stroke population. it is hypothesized that arm and leg cycling will transfer to improvements in walking in a post stroke population.

for those who have suffered a stroke, damage to the brain can result in a decreased ability to walk, thus decreasing quality of life in a significant way. traditionally, body weight supported treadmill training has been used for walking rehabilitation; however, this therapy requires specialized technicians, equipment, and facilities. arm and leg cycle ergometers, a device commonly found in a gym, could provide an inexpensive and readily accessible means for walking rehabilitation.

Eligibility criteria:
inclusion criteria: * stroke * lives within the victoria, vancouver island, and vancouver mainland communities exclusion criteria: * inability to stand for 5 minutes unassisted

Keywords: rehabilitation stroke walking interlimb connections